FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2088228080> ?p ?o ?g. }

• W2088228080 endingPage "185" @default.
• W2088228080 startingPage "177" @default.
• W2088228080 abstract "Background Tumor necrosis factor (TNF)-α is produced by macrophages and other cells, and is believed to participate in granulomatous inflammation. Targeted antagonism of TNF-α has been proposed as a novel treatment strategy for sarcoidosis. Etanercept is a dimeric fusion protein that binds specifically to TNF-α, rendering it biologically inactive. Objective To assess whether etanercept has potential efficacy in the treatment of progressive pulmonary sarcoidosis. Design Prospective, open-label, phase-2 treatment trial. Setting Mayo Clinic, Rochester, MN. Patients Stage II or III progressive pulmonary sarcoidosis. Intervention Etanercept, 25 mg subcutaneously twice weekly. Measurements Pulmonary function, chest radiographs, dyspnea, and TNF-α levels in serum and BAL fluid. Results The study was terminated after the enrollment of 17 patients due to an early-stop clause of the pretrial study design related to excessive treatment failures. Neither absolute levels of TNF-α nor TNF-α activity in the serum, BAL fluid, or alveolar macrophages were able to predict which patients would respond to etanercept. Conclusions In patients with progressive stage II or III pulmonary sarcoidosis, etanercept was frequently associated with early or late treatment failure. These data would not support the design of a large multicenter randomized trial comparing etanercept with conventional corticosteroid therapy. Tumor necrosis factor (TNF)-α is produced by macrophages and other cells, and is believed to participate in granulomatous inflammation. Targeted antagonism of TNF-α has been proposed as a novel treatment strategy for sarcoidosis. Etanercept is a dimeric fusion protein that binds specifically to TNF-α, rendering it biologically inactive. To assess whether etanercept has potential efficacy in the treatment of progressive pulmonary sarcoidosis. Prospective, open-label, phase-2 treatment trial. Mayo Clinic, Rochester, MN. Stage II or III progressive pulmonary sarcoidosis. Etanercept, 25 mg subcutaneously twice weekly. Pulmonary function, chest radiographs, dyspnea, and TNF-α levels in serum and BAL fluid. The study was terminated after the enrollment of 17 patients due to an early-stop clause of the pretrial study design related to excessive treatment failures. Neither absolute levels of TNF-α nor TNF-α activity in the serum, BAL fluid, or alveolar macrophages were able to predict which patients would respond to etanercept. In patients with progressive stage II or III pulmonary sarcoidosis, etanercept was frequently associated with early or late treatment failure. These data would not support the design of a large multicenter randomized trial comparing etanercept with conventional corticosteroid therapy." @default.
• W2088228080 created "2016-06-24" @default.
• W2088228080 creator A5007539897 @default.
• W2088228080 creator A5012967877 @default.
• W2088228080 creator A5012970528 @default.
• W2088228080 creator A5034276801 @default.
• W2088228080 creator A5051289606 @default.
• W2088228080 creator A5053804590 @default.
• W2088228080 creator A5089128381 @default.
• W2088228080 date "2003-07-01" @default.
• W2088228080 modified "2023-10-18" @default.
• W2088228080 title "Etanercept for the Treatment of Stage II and III Progressive Pulmonary Sarcoidosis" @default.
• W2088228080 cites W153497978 @default.
• W2088228080 cites W1967956104 @default.
• W2088228080 cites W1968823758 @default.
• W2088228080 cites W1987782497 @default.
• W2088228080 cites W1995873188 @default.
• W2088228080 cites W2000894943 @default.
• W2088228080 cites W2010324559 @default.
• W2088228080 cites W2020979111 @default.
• W2088228080 cites W2038535814 @default.
• W2088228080 cites W2054941139 @default.
• W2088228080 cites W2057123987 @default.
• W2088228080 cites W2072120170 @default.
• W2088228080 cites W2092098243 @default.
• W2088228080 cites W2098767548 @default.
• W2088228080 cites W2153205631 @default.
• W2088228080 cites W2158962866 @default.
• W2088228080 cites W2163899954 @default.
• W2088228080 cites W2168106968 @default.
• W2088228080 cites W2170904073 @default.
• W2088228080 cites W2314052274 @default.
• W2088228080 cites W2604596332 @default.
• W2088228080 cites W4210995779 @default.
• W2088228080 cites W4245089651 @default.
• W2088228080 doi "https://doi.org/10.1378/chest.124.1.177" @default.
• W2088228080 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12853521" @default.
• W2088228080 hasPublicationYear "2003" @default.
• W2088228080 type Work @default.
• W2088228080 sameAs 2088228080 @default.
• W2088228080 citedByCount "352" @default.
• W2088228080 countsByYear W20882280802012 @default.
• W2088228080 countsByYear W20882280802013 @default.
• W2088228080 countsByYear W20882280802014 @default.
• W2088228080 countsByYear W20882280802015 @default.
• W2088228080 countsByYear W20882280802016 @default.
• W2088228080 countsByYear W20882280802017 @default.
• W2088228080 countsByYear W20882280802018 @default.
• W2088228080 countsByYear W20882280802019 @default.
• W2088228080 countsByYear W20882280802020 @default.
• W2088228080 countsByYear W20882280802021 @default.
• W2088228080 countsByYear W20882280802022 @default.
• W2088228080 countsByYear W20882280802023 @default.
• W2088228080 crossrefType "journal-article" @default.
• W2088228080 hasAuthorship W2088228080A5007539897 @default.
• W2088228080 hasAuthorship W2088228080A5012967877 @default.
• W2088228080 hasAuthorship W2088228080A5012970528 @default.
• W2088228080 hasAuthorship W2088228080A5034276801 @default.
• W2088228080 hasAuthorship W2088228080A5051289606 @default.
• W2088228080 hasAuthorship W2088228080A5053804590 @default.
• W2088228080 hasAuthorship W2088228080A5089128381 @default.
• W2088228080 hasConcept C126322002 @default.
• W2088228080 hasConcept C17991360 @default.
• W2088228080 hasConcept C203014093 @default.
• W2088228080 hasConcept C2777226972 @default.
• W2088228080 hasConcept C2779722408 @default.
• W2088228080 hasConcept C2781301800 @default.
• W2088228080 hasConcept C71924100 @default.
• W2088228080 hasConcept C90924648 @default.
• W2088228080 hasConceptScore W2088228080C126322002 @default.
• W2088228080 hasConceptScore W2088228080C17991360 @default.
• W2088228080 hasConceptScore W2088228080C203014093 @default.
• W2088228080 hasConceptScore W2088228080C2777226972 @default.
• W2088228080 hasConceptScore W2088228080C2779722408 @default.
• W2088228080 hasConceptScore W2088228080C2781301800 @default.
• W2088228080 hasConceptScore W2088228080C71924100 @default.
• W2088228080 hasConceptScore W2088228080C90924648 @default.
• W2088228080 hasIssue "1" @default.
• W2088228080 hasLocation W20882280801 @default.
• W2088228080 hasLocation W20882280802 @default.
• W2088228080 hasOpenAccess W2088228080 @default.
• W2088228080 hasPrimaryLocation W20882280801 @default.
• W2088228080 hasRelatedWork W1943494332 @default.
• W2088228080 hasRelatedWork W1953454557 @default.
• W2088228080 hasRelatedWork W1971028997 @default.
• W2088228080 hasRelatedWork W2015993259 @default.
• W2088228080 hasRelatedWork W2047751757 @default.
• W2088228080 hasRelatedWork W2064645888 @default.
• W2088228080 hasRelatedWork W2095450130 @default.
• W2088228080 hasRelatedWork W2137887838 @default.
• W2088228080 hasRelatedWork W2345141018 @default.
• W2088228080 hasRelatedWork W2597927063 @default.
• W2088228080 hasVolume "124" @default.
• W2088228080 isParatext "false" @default.
• W2088228080 isRetracted "false" @default.
• W2088228080 magId "2088228080" @default.
• W2088228080 workType "article" @default.